Rx (Prescription Medicine)
USD $ 7.00
Celdaz 100mg 注射剂是一种含有活性成分 Bevacizumab 的药物。Bevacizumab 是一种靶向治疗药物，具体而言是单克隆抗体，其作用机制是抑制血管内皮生长因子（VEGF）。VEGF 是一种促进新血管生长的蛋白质。通过阻断 VEGF，Celdaz 有助于减少肿瘤的血液供应，从而减缓或停止其生长。它主要与化疗联合使用，用于治疗某些类型的癌症，包括转移性结直肠癌、非小细胞肺癌、胶质母细胞瘤以及转移性肾细胞癌。Celdaz 100mg 注射剂的剂量和用法应严格由合格的医疗专业人员根据具体的癌症类型、分期以及患者的整体健康状况来确定。常见的不良反应可能包括高血压、尿蛋白、鼻出血和疲劳。虽然罕见，但严重的不良反应也可能发生，需要立即就医。Celdaz 100mg 注射剂应储存在室温、避光的环境中，且不应冷冻。始终请咨询您的医生或药师以获取详细的信息和指导。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Brand Name | |
| Strength |
未库存此 exact 强度的其他品牌，因此这些是其他强度的 Dacarbazine. 未经开方医生建议，请勿更改剂量。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
